{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:30:37Z","timestamp":1790767837754,"version":"4.1.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\u03949-Tetrahydrocannabinol (THC) is the active metabolite of cannabis. THC causes cell death in vitro through the activation of complex signal transduction pathways. However, the role that the cannabinoid 1 and 2 receptors (CB1-R and CB2-R) play in this process is less clear. We therefore investigated the role of the CB-Rs in mediating apoptosis in 3 leukemic cell lines and performed microarray and immunoblot analyses to establish further the mechanism of cell death. We developed a novel flow cytometric technique of measuring the expression of functional receptors and used combinations of selective CB1-R and CB2-R antagonists and agonists to determine their individual roles in this process. We have shown that THC is a potent inducer of apoptosis, even at 1 \u00d7 IC50 (inhibitory concentration 50%) concentrations and as early as 6 hours after exposure to the drug. These effects were seen in leukemic cell lines (CEM, HEL-92, and HL60) as well as in peripheral blood mononuclear cells. Additionally, THC did not appear to act synergistically with cytotoxic agents such as cisplatin. One of the most intriguing findings was that THC-induced cell death was preceded by significant changes in the expression of genes involved in the mitogen-activated protein kinase (MAPK) signal transduction pathways. Both apoptosis and gene expression changes were altered independent of p53 and the CB-Rs.<\/jats:p>","DOI":"10.1182\/blood-2004-03-1182","type":"journal-article","created":{"date-parts":[[2004,9,29]],"date-time":"2004-09-29T01:28:26Z","timestamp":1096421306000},"page":"1214-1221","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":70,"title":["Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway"],"prefix":"10.1182","volume":"105","author":[{"given":"Thomas","family":"Powles","sequence":"first","affiliation":[{"name":"From the New Drug Study Group, St Bartholomew's Hospital (SBH), London, United Kingdom; the Department of Medical Oncology, SBH, London, United Kingdom; the Centre for Cancer Therapeutics, Institute of Cancer Research, Surrey, United Kingdom; the Department of Medical Oncology, Charterhouse Square, London, United Kingdom; and the Barry Reed Oncology Laboratory, SBH, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert te","family":"Poele","sequence":"additional","affiliation":[{"name":"From the New Drug Study Group, St Bartholomew's Hospital (SBH), London, United Kingdom; the Department of Medical Oncology, SBH, London, United Kingdom; the Centre for Cancer Therapeutics, Institute of Cancer Research, Surrey, United Kingdom; the Department of Medical Oncology, Charterhouse Square, London, United Kingdom; and the Barry Reed Oncology Laboratory, SBH, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Shamash","sequence":"additional","affiliation":[{"name":"From the New Drug Study Group, St Bartholomew's Hospital (SBH), London, United Kingdom; the Department of Medical Oncology, SBH, London, United Kingdom; the Centre for Cancer Therapeutics, Institute of Cancer Research, Surrey, United Kingdom; the Department of Medical Oncology, Charterhouse Square, London, United Kingdom; and the Barry Reed Oncology Laboratory, SBH, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Chaplin","sequence":"additional","affiliation":[{"name":"From the New Drug Study Group, St Bartholomew's Hospital (SBH), London, United Kingdom; the Department of Medical Oncology, SBH, London, United Kingdom; the Centre for Cancer Therapeutics, Institute of Cancer Research, Surrey, United Kingdom; the Department of Medical Oncology, Charterhouse Square, London, United Kingdom; and the Barry Reed Oncology Laboratory, SBH, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Propper","sequence":"additional","affiliation":[{"name":"From the New Drug Study Group, St Bartholomew's Hospital (SBH), London, United Kingdom; the Department of Medical Oncology, SBH, London, United Kingdom; the Centre for Cancer Therapeutics, Institute of Cancer Research, Surrey, United Kingdom; the Department of Medical Oncology, Charterhouse Square, London, United Kingdom; and the Barry Reed Oncology Laboratory, SBH, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Joel","sequence":"additional","affiliation":[{"name":"From the New Drug Study Group, St Bartholomew's Hospital (SBH), London, United Kingdom; the Department of Medical Oncology, SBH, London, United Kingdom; the Centre for Cancer Therapeutics, Institute of Cancer Research, Surrey, United Kingdom; the Department of Medical Oncology, Charterhouse Square, London, United Kingdom; and the Barry Reed Oncology Laboratory, SBH, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Oliver","sequence":"additional","affiliation":[{"name":"From the New Drug Study Group, St Bartholomew's Hospital (SBH), London, United Kingdom; the Department of Medical Oncology, SBH, London, United Kingdom; the Centre for Cancer Therapeutics, Institute of Cancer Research, Surrey, United Kingdom; the Department of Medical Oncology, Charterhouse Square, London, United Kingdom; and the Barry Reed Oncology Laboratory, SBH, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Man","family":"Liu","sequence":"additional","affiliation":[{"name":"From the New Drug Study Group, St Bartholomew's Hospital (SBH), London, United Kingdom; the Department of Medical Oncology, SBH, London, United Kingdom; the Centre for Cancer Therapeutics, Institute of Cancer Research, Surrey, United Kingdom; the Department of Medical Oncology, Charterhouse Square, London, United Kingdom; and the Barry Reed Oncology Laboratory, SBH, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021219130793800_REF1","doi-asserted-by":"crossref","unstructured":"Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3: 745-755.","DOI":"10.1038\/nrc1188"},{"key":"2020021219130793800_REF2","doi-asserted-by":"crossref","unstructured":"de Petrocellis L, Melck D, Palmisano A, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A. 1998;95: 8375-8380.","DOI":"10.1073\/pnas.95.14.8375"},{"key":"2020021219130793800_REF3","doi-asserted-by":"crossref","unstructured":"Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 2000;6: 313-319.","DOI":"10.1038\/73171"},{"key":"2020021219130793800_REF4","unstructured":"Sanchez C, de Ceballos MI, del Pulgar TG, et al. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res. 2001;61: 5784-5789."},{"key":"2020021219130793800_REF5","doi-asserted-by":"crossref","unstructured":"Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346: 561-564.","DOI":"10.1038\/346561a0"},{"key":"2020021219130793800_REF6","doi-asserted-by":"crossref","unstructured":"Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365: 61-65.","DOI":"10.1038\/365061a0"},{"key":"2020021219130793800_REF7","doi-asserted-by":"crossref","unstructured":"Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232: 54-61.","DOI":"10.1111\/j.1432-1033.1995.tb20780.x"},{"key":"2020021219130793800_REF8","doi-asserted-by":"crossref","unstructured":"Carayon P, Marchand J, Dussossoy D, et al. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood. 1998;92: 3605-3615.","DOI":"10.1182\/blood.V92.10.3605"},{"key":"2020021219130793800_REF9","doi-asserted-by":"crossref","unstructured":"Ruiz L, Miguel A, Diaz-Laviada I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. 1999;458: 400-444.","DOI":"10.1016\/S0014-5793(99)01073-X"},{"key":"2020021219130793800_REF10","doi-asserted-by":"crossref","unstructured":"McKallip RJ, Lombard C, Fisher M, et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 2002;100: 627-634.","DOI":"10.1182\/blood-2002-01-0098"},{"key":"2020021219130793800_REF11","doi-asserted-by":"crossref","unstructured":"Galve-Roperh I, Rueda D, Gomez del Pulgar T, Velasco G, Guzman M. Mechanism of extracellular signal-regulated kinase activation by the CB1 cannabinoid receptor. Mol Pharmacol. 2002;62: 1385-1392.","DOI":"10.1124\/mol.62.6.1385"},{"key":"2020021219130793800_REF12","doi-asserted-by":"crossref","unstructured":"Sarafian TA, Tashkin DP, Roth MD. Marijuana smoke and Delta9-tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis. Toxicol Appl Pharmacol. 2001;174: 264-272.","DOI":"10.1006\/taap.2001.9224"},{"key":"2020021219130793800_REF13","doi-asserted-by":"crossref","unstructured":"Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical applications of pharmacokinetic-pharmacodynamic models. Clin Phamacokin. 1981;6: 429-453.","DOI":"10.2165\/00003088-198106060-00002"},{"key":"2020021219130793800_REF14","doi-asserted-by":"crossref","unstructured":"Gifford AN, Tang Y, Gatley SJ, Volkow ND, Lan R, Makriyannis A. Effect of the cannabinoid receptor SPECT agent, am 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett. 1997;238: 84-86.","DOI":"10.1016\/S0304-3940(97)00851-3"},{"key":"2020021219130793800_REF15","doi-asserted-by":"crossref","unstructured":"Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sci. 1995;56: 1949-1955.","DOI":"10.1016\/0024-3205(95)00175-6"},{"key":"2020021219130793800_REF16","doi-asserted-by":"crossref","unstructured":"Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A. 1995;92: 376-3380.","DOI":"10.1073\/pnas.92.8.3376"},{"key":"2020021219130793800_REF17","doi-asserted-by":"crossref","unstructured":"Liu WM, Stimson LA, Joel SP. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukemia cells: synergistic interactions with anti-leukaemic agents. Br J Cancer. 2002;86: 472-1478.","DOI":"10.1038\/sj.bjc.6600288"},{"key":"2020021219130793800_REF18","doi-asserted-by":"crossref","unstructured":"Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S. Effect of hemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene. 2004;23: 981-990.","DOI":"10.1038\/sj.onc.1207294"},{"key":"2020021219130793800_REF19","doi-asserted-by":"crossref","unstructured":"Liu WM, Strauss SJ, Chaplin T, et al. s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J. 2004;5: 247-254.","DOI":"10.1038\/sj.thj.6200351"},{"key":"2020021219130793800_REF20","doi-asserted-by":"crossref","unstructured":"Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42: 327-360.","DOI":"10.2165\/00003088-200342040-00003"},{"key":"2020021219130793800_REF21","doi-asserted-by":"crossref","unstructured":"Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 1998;436: 6-10.","DOI":"10.1016\/S0014-5793(98)01085-0"},{"key":"2020021219130793800_REF22","doi-asserted-by":"crossref","unstructured":"Gomez del Pulgar T, Velasco G, Guzman M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B\/Akt. Biochem J. 2000; 347: 369-373.","DOI":"10.1042\/bj3470369"},{"key":"2020021219130793800_REF23","doi-asserted-by":"crossref","unstructured":"Bratthauer GL. The avidin-biotin complex (ABC) method and other avidin-biotin binding methods. Methods Mol Biol. 1999;115: 203-214.","DOI":"10.1385\/1-59259-213-9:203"},{"key":"2020021219130793800_REF24","doi-asserted-by":"crossref","unstructured":"de Jong MO, Westerman Y, Wagemaker G, Wognum AW. Coexpression of Kit and the receptors for erythropoietin, interleukin 6 and GM-CSF on hemopoietic cells. Stem Cells. 1997;15: 275-285.","DOI":"10.1002\/stem.150275"},{"key":"2020021219130793800_REF25","doi-asserted-by":"crossref","unstructured":"Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol. 1998;359: 1-18.","DOI":"10.1016\/S0014-2999(98)00649-9"},{"key":"2020021219130793800_REF26","doi-asserted-by":"crossref","unstructured":"Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258: 1946-1949.","DOI":"10.1126\/science.1470919"},{"key":"2020021219130793800_REF27","doi-asserted-by":"crossref","unstructured":"Sarker KP, Maruyama I. Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts. Cell Mol Life Sci. 2003;60: 1200-1208.","DOI":"10.1007\/s00018-003-3055-2"},{"key":"2020021219130793800_REF28","doi-asserted-by":"crossref","unstructured":"Sokal DM, Elmes SJ, Kendall DA,. Chapman V. Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology. 2003;45: 404-411.","DOI":"10.1016\/S0028-3908(03)00195-3"},{"key":"2020021219130793800_REF29","doi-asserted-by":"crossref","unstructured":"Casanova ML, Blazquez C, Martinez-Palacio J, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003;111: 43-50.","DOI":"10.1172\/JCI200316116"},{"key":"2020021219130793800_REF30","doi-asserted-by":"crossref","unstructured":"Konishi A, Shimizu S, Hirota J, et al. Involvement of histone H1.2 in apoptosis induced by DNA double-strand breaks. Cell. 2003;114: 673-688.","DOI":"10.1016\/S0092-8674(03)00719-0"},{"key":"2020021219130793800_REF31","doi-asserted-by":"crossref","unstructured":"Farooq A, Chaturvedi G, Mujtaba S, et al. Solution structure of ERK2 binding domain of MAPK phosphatase MKP-3: structural insights into MKP-3 activation by ERK2. Mol Cell. 2001;7: 387-399.","DOI":"10.1016\/S1097-2765(01)00186-1"},{"key":"2020021219130793800_REF32","doi-asserted-by":"crossref","unstructured":"Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell. 1991;75: 487-493.","DOI":"10.1016\/0092-8674(93)90383-2"},{"key":"2020021219130793800_REF33","doi-asserted-by":"crossref","unstructured":"Reffas S, Schlegel W. Compartment-specific regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) by ERK-dependent and non-ERK-dependent inductions of MAPK phosphatase (MKP)-3 and MKP-1 in differentiating P19 cells. Biochem J. 2000;352: 701-708.","DOI":"10.1042\/bj3520701"},{"key":"2020021219130793800_REF34","unstructured":"Rossig L, Hermann C, Haendeler J, Assmus B, Zeiher AM, Dimmeler S. Angiotensin II-induced up-regulation of MAP kinase phosphatase-3 mRNA levels mediates endothelial cell apoptosis. Basic Res Cardiol. 2002;97: 1-8."},{"key":"2020021219130793800_REF35","doi-asserted-by":"crossref","unstructured":"Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6\/MKP-3 in pancreatic cancer. Am J Pathol. 2003;162: 1807-1815.","DOI":"10.1016\/S0002-9440(10)64315-5"},{"key":"2020021219130793800_REF36","unstructured":"Li SP, Junttila MR, Han J, Kahari VM, Westermarck J. p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein\/extracellular signal-regulated kinase kinase1,2. Cancer Res. 2003;63: 3473-3477."},{"key":"2020021219130793800_REF37","doi-asserted-by":"crossref","unstructured":"Gallily R, Even-Chena T, Katzavian G, Lehmann D, Dagan A, Mechoulam R. Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma. 2003;44: 1767-1773.","DOI":"10.1080\/1042819031000103917"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/3\/1214\/1705920\/zh800305001214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/3\/1214\/1705920\/zh800305001214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:58:12Z","timestamp":1581555492000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/3\/1214\/19628\/Cannabisinduced-cytotoxicity-in-leukemic-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-03-1182","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,1]]}}}